Looking forward to 2020 healthcare investment through 2019 domestic healthcare investment and financing

In 2019, the Shanghai Stock Exchange launched the science and technology innovation board, coupled with a number of industrial support policies, to promote the medical and health industry to usher in a new outbreak point At this time, medical health is becoming a new engine of the national economy and one of the pillar industries of the new generation of scientific and technological revolution and industrial transformation depending on the strength of hard science and technology In view of this, at the end of this year and the beginning of this year, EUROHEALTH combed the investment and financing situation of the medical health industry in the past year, and based on policy, market, capital and other factors, made five predictions on the medical investment trend in 2020 According to statistics, in 2019, China's medical and health industry received a total financing amount of about 111.22 billion yuan, with 570 financing events, with an average of 47.5 financing events per month As can be seen from the above figure, the total financing amount in January, may and November exceeded 10 billion yuan Among them, 59 financing events took place in January with a total financing amount of 15.549 billion yuan; 41 financing events took place in May with a total financing amount of 14.218 billion yuan; 54 financing events took place in November with a total financing amount of 27.068 billion yuan According to statistics, in 2019, among the financing events in China's medical and health industry, 203 financing events took the lead in the pharmaceutical manufacturing sector, accounting for 35.61%; 124 financing events took place in the medical device sector, accounting for 21.75%, with the potential to catch up with the former As can be seen from the above figure, the investment heat in China's pharmaceutical manufacturing sector has not subsided in 2019, accounting for more than 30% in each month, and even more than 40% in February, may and July, 43.59%, 47.62% and 43.14% respectively It is worth noting that in April and October, the number of financing events in the field of medical devices exceeded that in the field of pharmaceutical manufacturing In addition, gene technology and Internet medicine are two fields Although the news is continuous, there are no multiple financing events, which makes us feel like "a lot of thunder and a little rain" According to statistics, in 2019, the financing of medical and health industry in Beijing, Shanghai and Guangdong was the most active Among them, there were 139 financing events in Beijing, accounting for 24.39%; 125 financing events in Shanghai, accounting for 21.93%; 81 financing events in Guangdong, accounting for 14.21% It is worth noting that the medical industry in Jiangsu and Zhejiang is also relatively active, with 78 and 53 financing events respectively According to statistics, the financing of China's medical and health industry in 2019 is mainly concentrated in two rounds a and B Among them, 163 cases occurred in round a financing, accounting for 28.60%; 96 cases occurred in round B financing, accounting for 16.84% In addition, strategic investment is also the investment mode favored by the current capital According to the data, 83 strategic investments occurred in 2019, accounting for 14.56% Top 10 financing amount of China's medical and health industry in 2019: Baiji Shenzhou wins the title On November 1, 2019, Baiji Shenzhou and Amgen announced to reach a global cancer strategic partnership Amgen bought 20.5% of Baiji's Shenzhou shares for about $2.7 billion in cash, or $174.85 per ads share On May 10, 2019, in the financial statements of the first quarter of 2019, Jingdong group announced the formal establishment of Jingdong health sub group In addition, Jingdong and investors such as cpechina fund, CICC capital and baring Asia reached a final agreement on the financing of Jingdong healthy series a preferred shares, with the financing amount expected to exceed US $1 billion On November 15, 2019, meinian Health announced that Alibaba (China) Network Technology Co., Ltd subscribed 159 million non-public shares of meinian health with 1.84 billion yuan and obtained 4.06% shares In addition, meinian health also issued 18 million shares to Boshi Fund Management Co., Ltd., with a subscription amount of about 210 million yuan On January 25, 2019, Boyu capital invested $249 million in Hansen pharmaceutical at a total cost, holding about 3.00% of Hansen's pre IPO equity On April 24, 2019, Penguin almond group announced that it has completed a new round of financing of US $250 million, which is jointly led by Country Garden venture capital, Tencent and Jihui capital, followed by CMB international, harvest wealth, China Russia investment fund, Sequoia China, shengshijing group and AVIC trust On October 18, 2019, Taimei medical technology officially announced the completion of round e and round e + financing with a total amount of 1.5 billion yuan, respectively led by Tiger Global Fund and Tencent, followed by Softbank China, Chenxing capital, Kaifeng venture capital, Saifu investment fund, Zheshang venture capital and ivy capital On May 25, 2019, Huada Zhizao, a subsidiary of Huada gene group, completed round a financing of 200 million US dollars The financing is the largest financial transaction in the field of gene sequencing in China so far This round of financing is invested by CITIC Jinshi, Songhe capital and Dongzheng capital On August 11, 2019, Chongqing Harper and heimaqi Airlines respectively increased their capital to Harbin Pharmaceutical Group with cash of 805 million yuan and 403 million yuan, respectively subscribed 435 million yuan and 218 million yuan of new registered capital of Harbin Pharmaceutical Group, accounting for 10% and 5% of equity The total amount of the two capital increases reached 1.208 billion yuan On May 23, 2019, Ellis pharmaceutical announced that it had completed the first round of financing with a financing amount of RMB 1.18 billion It is reported that this round of financing is led by Shiyu capital Zhengxingu innovation capital, sifanghe, Gongqingcheng Hanren, Yuansheng venture capital, Gaoke Xinjun, Gaoke Xinchuang, Guotou Chuang he, Deyi capital, Huaxin Century Investment and Qianlong capital jointly participate in the investment On September 7, 2019, Guoke Hengtai (Beijing) Medical Technology Co., Ltd officially announced the completion of round C financing, with an overall financing scale of more than 1.1 billion yuan This financing is led by Taikang Life Insurance, followed by Tonghe Yucheng fund, China Merchants capital, Yongliu capital, Junlian capital, Sherpa fund, guokejia Heshi fund, Shanghai Langwen Department fund, etc With the continuous breakthrough of global biomedical technology, China's innovative pharmaceutical industry has reached an unprecedented grand occasion with the capital In the national medium and long term plan for the development of science and nuclear technology (2006-2020), major new drug creation is one of the 16 major projects By 2020, innovative drugs have also ushered in a key node of their development On the one hand, it needs to be "reviewed" by the state; on the other hand, innovative drugs will continue to embark on a new journey At present, the development of innovative drugs in China is mainly focused on the development of monoclonal antibodies for cancer and autoimmune diseases, while there are relatively few innovative drugs for some functional protein deletions and cellular immunotherapy Therefore, in 2020, China's medical investment in innovative drugs may move in the direction of recombinant protein and cellular immunotherapy In recent years, the state attaches great importance to the development of traditional Chinese medicine industry The guiding opinions on strengthening the scientific and technological innovation of health services of traditional Chinese medicine mentioned that by 2030, China should establish a scientific and technological innovation system of health services of traditional Chinese medicine with the whole life cycle health service chain of prevention, health care and rehabilitation as the core, further improve the service capacity and level of traditional Chinese medicine, and boost the construction of healthy China In addition, Article 9 of the law of the people's Republic of China on basic medical and health promotion passed on December 28, 2019 clearly states that the country will vigorously develop the cause of traditional Chinese medicine, adhere to the combination of traditional Chinese medicine and Western medicine, inheritance and innovation, and play the unique role of traditional Chinese medicine in the cause of medical and health care In other words, the industry of traditional Chinese medicine ushers in its best development opportunities In 2020, this field will also become an important plate for major investment institutions to compete for layout In the health China action 2030 issued by the State Council in July 2019, the State Council proposed the development direction of gateway moving forward and disease prevention, and set "health management" as the common goal from top to bottom "How to promote one's health through health management and reduce medical expenses" has become a common concern of contemporary people In the wave of mobile medicine, the medical and health services that people receive are connected in a digital, intelligent and personalized way Health management has been integrated into all aspects of people's life, such as diet control, body management, sleep management and so on In 2020, the health management industry may undergo a round of reshuffle, and the entry of capital will also make this competition more intense, interesting and worthy of expectation On June 29, 2019, the 11th meeting of the Standing Committee of the 13th National People's Congress voted to adopt the vaccine management law, which came into force on December 1, 2019 Previously, Jiao Hong, director of the State Drug Administration, said that China's annual vaccine production capacity has exceeded 1 billion doses However, such capacity still fails to meet the market demand, especially for innovative vaccines Under the double drive of policy and market, China's vaccine industry will usher in new development opportunities in 2020 In addition, in 2019, as soon as kangxinuo biology was listed in Hong Kong stock market, it was sought after by the capital circle Therefore, vaccine preparation may become one of the important sectors of medical investment in 2020.